# María-Victoria Mateos

Source: https://onco.cc/people/maria-victoria-mateos/  
OnCo record `maria-victoria-mateos` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led ALCYONE and the smouldering myeloma trials that showed treating early can delay progression to active disease.

## Summary

María-Victoria Mateos (Salamanca) was principal investigator of ALCYONE, which established daratumumab with bortezomib-melphalan-prednisone in transplant-ineligible myeloma, and of the Spanish QuiRedex and the international AQUILA trials showing that treating high-risk smouldering myeloma with lenalidomide-dexamethasone or daratumumab delays progression and improves survival. She leads the Spanish Myeloma Group and IMWG guideline work.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: myeloma; smouldering; spain
- Role: Consultant Hematologist and Director of the Myeloma Program, University Hospital of Salamanca
- Specialisms: Multiple myeloma; Smouldering myeloma; Daratumumab combinations; Early intervention

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Mateos%20MV%5BAuthor%5D%20myeloma

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- technologies: [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/)
- targets: [CD38](https://onco.cc/targets/cd38/)
- institutions: [University Hospital of Salamanca / IBSAL](https://onco.cc/institutions/hospital-universitario-salamanca/)

---
JSON: https://onco.cc/api/v1/entities/maria-victoria-mateos.json